Updated Oct 15, 2026
/S&P 500 Shiller CAPE Ratio hits 40 as bond yields reach 2002 highs/Proven Media Solutions urges unified corporate strategy for divided Washington/US Stock Futures Fall as AI Valuation Concerns Offset Anthropic Revenue Growth and TSMC Record Profit/Anthropic revenue rises 45% to $16.8 billion as AI stocks fall/U.S. Deficit Near $2 Trillion Amid 5% Treasury Yields/Michael Penix Jr. expected to start for Falcons against Bears/S&P 500 Shiller CAPE Ratio hits 40 as bond yields reach 2002 highs/Proven Media Solutions urges unified corporate strategy for divided Washington/US Stock Futures Fall as AI Valuation Concerns Offset Anthropic Revenue Growth and TSMC Record Profit/Anthropic revenue rises 45% to $16.8 billion as AI stocks fall/U.S. Deficit Near $2 Trillion Amid 5% Treasury Yields/Michael Penix Jr. expected to start for Falcons against Bears
NewsSOS
← NewswireMarkets

Pomerantz Law Opens Investor Investigation Into NovoCure Limited

NEW YORK, July 9. Pomerantz LLP said it is investigating claims on behalf of investors in NovoCure Limited (NASDAQ: NVCR), according to a release. The firm named Danielle Peyton as the contact attorney. The release gave no description of the specific claims under review.

By Corinne Ashford2 min read
Share

Key takeaways

  • Pomerantz LLP announced on July 9 that it is investigating claims on behalf of investors in NovoCure Limited (NASDAQ: NVCR).
  • The release did not describe the specific claims, alleged misconduct, time period, or any regulatory action under review.
  • It did not indicate whether any formal litigation has been filed against NovoCure.
  • Danielle Peyton was named as the contact attorney, reachable at 646-581-9980, extension 7980, or [email protected].
  • Pomerantz LLP made no additional disclosures about NovoCure's business, financial results, or any related proceedings.

NEW YORK, July 9. Pomerantz LLP said it is investigating claims on behalf of investors in NovoCure Limited (NASDAQ: NVCR), according to a release. The firm named Danielle Peyton as the contact attorney. The release gave no description of the specific claims under review.

Scope of the probe

Pomerantz LLP identified NovoCure Limited, trading on Nasdaq under the symbol NVCR, as the subject of the inquiry. No description of alleged misconduct was included, and the release cited no specific time period or regulatory action. It also did not indicate whether formal litigation has been filed.

How investors can reach the firm

Peyton can be reached at 646-581-9980, extension 7980, or by email at [email protected]. The release listed New York as the firm's base for the announcement. Pomerantz LLP made no additional disclosures about NovoCure's business, financial results, or any proceedings that may have prompted the investigation.

Note: The source release contained limited factual detail. This article reflects all available facts; no figures, allegations, or timelines were added.

Keep reading

All bulletins →
MarketsOctober 15, 2026

S&P 500 Shiller CAPE Ratio hits 40 as bond yields reach 2002 highs

The S&P 500 Shiller CAPE Ratio has risen to just over 40, a level close to the dot-com era record of 44 and significantly above its long-term average of 17. This valuation metric, which measures the index's 10-year inflation-adjusted…

2 min read
MarketsOctober 14, 2026

BlackRock Q3 earnings beat estimates on revenue and EPS

BlackRock reported third-quarter results that exceeded analyst expectations for both adjusted earnings per share and total revenue. The asset manager posted an adjusted EPS of $15.93, surpassing the consensus estimate of $14.30 by 11.4%…

2 min read
MarketsOctober 14, 2026

StockStory Flags Hexcel as Promising Industrials Stock Amid Sector Decline

StockStory has identified Hexcel (NYSE:HXL) as an industrials stock with promising prospects, while flagging Ingersoll Rand (NYSE:IR) and D.R. Horton (NYSE:DHI) as risky positions. The analysis comes as the industrial sector has tumbled by…

2 min read

Frequently asked

Who is investigating NovoCure Limited?

Pomerantz LLP, a firm based in New York, said it is investigating claims on behalf of NovoCure investors.

What specific claims or misconduct are being investigated?

The release gave no description of the specific claims or alleged misconduct, and cited no time period or regulatory action.

Has a lawsuit been filed against NovoCure?

The release did not indicate whether any formal litigation has been filed.

How can investors contact the firm?

Investors can reach contact attorney Danielle Peyton at 646-581-9980, extension 7980, or by email at [email protected].

Under what ticker does NovoCure Limited trade?

NovoCure Limited trades on Nasdaq under the symbol NVCR.